Har du astma eller KOL och är intresserad av att delta i någon av våra studier vid framtagning av nya läkemedel? Gå till vår sida för intresseanmälan här. |
Flow-volyme spirometry with 12-lead ECG
APS and IOS
Isocapnic hyperventilation
Cell biology
Cell culture
Induced sputum
Exhaled breath condensate - EBC
Fraktional Nitric Oxide - FeNO
Skåne University Hospital in Lund serves as a Regional and University hospital for southern health care region with 1.9 million inhabitants. It serves as local hospital for approximately 200 000 inhabitants and have access to a population of about 600 000 people within the range of 30 minutes driving distance by car or train.
At the department of Respiratory Medicine and Allergy we have two professors, Claes-Göran Löfdahl, head of the Lung medicine section of the institution for clinical sciences in Lund. His main area of research interest is directed towards COPD pathophysiology and epidemiology. Leif Bjermer has a position in asthma and allergy research and as such coordinator of the research unit for experimental lung biology. He is also responsible for the clinical trial unit for asthma, COPD and respiratory allergy.
Personal
Name | Position | Percent engagement |
Leif Bjermer | Head, Professor | 25 % |
Jaro Ankerst | Professor, MD, PhD | 25 % |
Alf Tunsäter | Senior lecturer, MD, PhD | 20 % |
Zuzana Diamant | Guest Professor, MD, PhD | 20 % |
Ellen Tufvesson | Assoc Prof, PhD | 100 % |
Georgia Papapostolou | MD, PhD | 50 % |
Mette Solum | Research administrator/nurse | 100 % |
Susann Ferm | Research nurse | 100 % |
Karina Kanzenbach | Research nurse | 100 % |
Tina Olsson | Research nurse | 100 % |
Maria Karremo | Research nurse | 100 % |
Anna Sikesjö | Research nurse assistant | 70 % |
Linnea Jarenbäck | Research ass, PhD | 100 % |
Sofia Mogren | BMA | 25 % |
In addition to the people directly involved in clinical trials, we have in the experimental unit for lung biology research access to people with advanced knowledge in molecular biology, biochemistry, proteomics and morphology.
Phase II studies
We have an ambulatory unit with 6 observational sleeper chairs. It is also possible to have 6 people staying overnight in beds. ECG ministration can be performed with telemetry for up to six patients at the same time. We do "first in patient" studies, while "first in man" studies are being done at the phase I unit, located in a separate place of the hospital.
Phase III studies
It's being done regular at our unit. We are mainly doing studies on asthma and COPD and occasionally on interstitial lung disorders (IPF, Sarcoidosis). Oncology studies are done in a separate unit at the clinic, with Ronny Öhman as responsible investigator.
Respiratory physiology
Testing for bronchial direct or indirect hyperresponsiveness
Wright spirometer (PC20)
PC20 metacholine test is being done according to ATS recommendations (Crapo 2000) with two minutes tidal volume breathing with different concentrations at output 0.13ml/min.
The unit has good experience in performing allergen provocation studies, preferably with the use of the Spira device to deliver bronchial allergen.
We are also familiar with the two minutes tidal breathing technique. We have also expertise in Nasal provocation testing.
Ergospirometry is being done with a Viasys CPX system (figure). By a combined protocol it is possible to measure oxygen uptake, oxygen puls and degree of dynamic hyperinflation parallell with an exercise provocation. Both bicycle and treadmill can be used even though we prefer treadmill as a more reliable exercise challenge. The patients are monitored by either 3 or 12 lead ECG.
We have access to a modern laboratory with fascilities as advanced biochemical analyses (ELISA, RIA) including eicosanoids and a wide range of cytokines and inflammatory markers, Cellular analyses, Differential cell counting, FACScann and cell cultures.
Induced sputum: (Devilbiss ultrasonic nebulizer, Sommerset PA, USA). The sputum plugs are processed and cell differential counting are performed on stained cytospins while the supernatant is stored at -80oC pending analysis. Our research lab facility among others with ELISA and radioimmunetechniques is available.
Exhaled breath condensate (EBC) (Echo screen, Jaeger gmB).
We are able to measure Eicosanoids and a limited numbers of cytokines.
Fraktional Nitric Oxide (FeNO) (NIOX, Aerocrine).
For measurement of exhaled breath Nitric Oxide concentration. By measuring with different flow (Range from 10 to 400ml) it is possible to calculate alveolar NO, Bronchial flux and Bronchial diffusion.
We have access to a modern bronchoscopy unit (Olympus videobronchoscope) with transportable fluorscope unit (Siemens). Bronchoscopy with Bronchoalveolar lavage (BAL), bronchial biopsies and Transbronchial biopsies (TBB) is regularly done also in clinical trials. BAL is being analysed with differential cell counting and lymphocyte sub typing (FACscan). Biochemical analyses can be done with the same repertoire as for induced sputum. Moreover, morphological analyses can be done including double and triple staining immunofluorescens and con-focal microscopy.
We are continuously collecting patients registered as interested in participating in clinical trials. Thus patients are recruited from different sources
A) Asthma and Allergy out-patient unit. Every year we have around 6000 patient visits in the outdoor apartment. Of those with asthma, the majority are asked to sign up for attending a possible clinical trial.
B) All patients referred to the hospital due to a COPD exacerbation are followed-up in our out door COPD department. All are registered and characterised according to severity, treatment etc.
C) Advertisement has proven be very effective attracting patients and healthy volonteers from regions outside the hospital. The potential study patients register themselves on our website.
D) We also actively recruit subjects interested to participate in clinical trials through a large epidemiological project called Scanian Airways (sv. “Skånska Luftvägar”) involving 17000 subjects over 50 years. Subjects with asthma, COPD or a smoke history more than 15 years are asked to fill in a questionnaire. Moreover they are asked to sign whether they are willing to participate in future clinical trials. Today we have 3000 subjects in our databaser.
Our overall aim is to deliver high quality clinical trials and as such being considered as reliable collaborative partners in asthma and COPD research. We have a skilled and experienced staff regularly being updated in the field. Parallel to the clinical trials, members of the group is being involved in advanced academic studies linked to the unit for experimental lung biology research, a translational research group focused on various aspects of lower airway inflammation. In all, the group involves around 20 active researchers.
By combining clinical trial activities with academic research, we have created a stable platform with enough economical and academic power for to secure future stability and progress. As a group we strive for to achieve long-term collaborations with reliable partners. This helps us to keep stability in the group and secure delivery of good data. It also helps us to build and preserve competence.